Roche: Chugai's optic disease drug meets primary endpoint

(CercleFinance.com) - Roche's Japanese subsidiary Chugai said its treatment for neuromyelitis optica spectrum disorder, a rare relapsing autoimmune disease that causes inflammation in the optic nerve, has met its primary endpoint in a late-stage trial.


A phase III study on Satralizumab has achieved its primary endpoint, which was defined as the time to first relapse.

In a statement, Roche said that a "statistically significant reduction" in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo.

Copyright (c) 2018 CercleFinance.com. All rights reserved.